Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sunshine Biopharma Inc.

1.70
+0.01000.59%
Post-market: 1.69-0.0101-0.59%19:56 EDT
Volume:133.98K
Turnover:230.16K
Market Cap:7.75M
PE:-0.23
High:1.81
Open:1.70
Low:1.66
Close:1.69
Loading ...

Nora Pharma Inc., Subsidiary of Sunshine Biopharma, Launches Generic Gabapentin in Canada

Reuters
·
Yesterday

Sunshine Biopharma Inc. Reports 18% Revenue Increase in Q1 2025, Net Loss Narrows to $1.18 Million

Reuters
·
20 May

Sunshine Biopharma Q1 EPS $(0.44) Up From $(2.00) YoY, Sales $8.90M Up From $7.54M YoY

Benzinga
·
16 May

Sunshine Biopharma Unit Rolls Out Afinitor Alternative Everolimus in Canadian Market

MT Newswires Live
·
21 Apr

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

ACCESS Newswire
·
21 Apr

Sunshine Biopharma Closes $2.5 Million Direct Offering

MT Newswires Live
·
03 Apr

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

ACCESS Newswire
·
03 Apr

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

Benzinga
·
02 Apr

Wall Street Awaits Trump's Tariff Plans as US Equity Futures Drop Pre-Bell

MT Newswires Live
·
02 Apr

Sunshine Biopharma Completes Additional Studies of mRNA Therapy for Liver Cancer; Shares Up Pre-Bell

MT Newswires Live
·
02 Apr

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

ACCESS Newswire
·
02 Apr

Top Premarket Gainers

MT Newswires Live
·
02 Apr

Sunshine Biopharma 2024 Revenue $34.9M Up From $24.1M YoY

Benzinga
·
02 Apr

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

ACCESS Newswire
·
02 Apr

Sunshine Biopharma Inc expected to post earnings of 11 cents a share - Earnings Preview

Reuters
·
29 Mar

Sunshine Biopharma signs agreement for rights to market two generic antibiotics

TipRanks
·
25 Mar

Sunshine Biopharma Inc expected to post earnings of 11 cents a share - Earnings Preview

Reuters
·
25 Mar

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

ACCESS Newswire
·
10 Mar

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

ACCESS Newswire
·
21 Jan

Sunshine Biopharma appoints Michel Roy as CCO

TIPRANKS
·
15 Jan